Similarly, galunisertib treatment increased sensitivity to anti‐PD‐L1 treatment in a CRC mouse tumor organoid model, as TGF‐β targeting treatment increased stromal PD‐L1 and T cell programmed cell death (PD)‐1 expression.60 The gene discussed is TGFB1; the disease is neoplasm.